Imatinib used in CML acts by -

• A. Blocking the action of P-glycoprotein
• B. Inhibiting Bcr/abl translocation via tyrosine kinase
• C. C-kit kinase inhibition
• D. Competitive inhibition of ATP binding site of Abl kinase